{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:18:43Z","timestamp":1769548723452,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clinthera.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T07:13:58Z","timestamp":1750835638000},"page":"807-812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Candesartan for Treatment of Migraine Headache: A Scoping Review"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7913-0135","authenticated-orcid":false,"given":"Ena Elizabeth L.","family":"Naoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3282-5846","authenticated-orcid":false,"given":"Mykha Marie B.","family":"Tabuzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5317-7369","authenticated-orcid":false,"given":"Roland Dominic G.","family":"Jamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.06.003_bib0001","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0002","doi-asserted-by":"crossref","unstructured":"GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23:344\u2013381. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3.","DOI":"10.1016\/S1474-4422(24)00038-3"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0003","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11916-019-0823-8","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults","volume":"23","author":"Dorosch","year":"2019","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0004","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.289.1.65","article-title":"Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial","volume":"289","author":"Tronvik","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0006","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0333102413515348","article-title":"A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomized, triple-blind, placebo-controlled, double cross-over study","volume":"34","author":"Stovner","year":"2014","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0007","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00415-020-09989-9","article-title":"Candesartan in migraine prevention: results from a retrospective real-world study","volume":"267","author":"Messina","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0008","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/s41598-021-83508-2","article-title":"Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study","volume":"11","author":"S\u00e1nchez-Rodr\u00edguez","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/03331024241248833","article-title":"CandeSpartan study: candesartan Spanish response-prediction and tolerability study in migraine","volume":"44","author":"Garc\u00eda-Azor\u00edn","year":"2024","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/head.13375","article-title":"Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018","volume":"58","author":"Loder","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0011","first-page":"72","article-title":"Medications for migraine prophylaxis","volume":"73","author":"Modi","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0012","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5694\/j.1326-5377.2008.tb02028.x","article-title":"Migraine prophylaxis","volume":"189","author":"Stark","year":"2008","journal-title":"Med J Aust"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231183166","article-title":"The effect of blood pressure lowering medications on the prevention of episodic migraine: a systematic review and meta-analysis","volume":"43","author":"Carcel","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0014","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s11606-013-2433-1","article-title":"Preventive pharmacologic treatments for episodic migraine in adults","volume":"28","author":"Shamliyan","year":"2013","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0015","first-page":"17","article-title":"Migraine headache prophylaxis","volume":"99","author":"Ha","year":"2019","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0016","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/CON.0000000000000957","article-title":"Preventive migraine treatment","volume":"27","author":"Burch","year":"2021","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0017","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1055\/s-0042-1755320","article-title":"Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II","volume":"80","author":"Santos","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0018","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s10194-019-1060-6","article-title":"Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine","volume":"20","author":"Kouremenos","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0019","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0020","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/CON.0000000000000199","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0021","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1212\/CON.0000000000000635","article-title":"Preventive therapy of migraine","volume":"24","author":"Schwedt","year":"2018","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0022","series-title":"Migraine in Adults: Preventive Pharmacologic Treatments","author":"Shamliyan","year":"2013"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0023","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11940-019-0559-0","article-title":"Other preventive anti-migraine treatments: ACE inhibitors, ARBs, calcium channel blockers, serotonin antagonists, and NMDA receptor antagonists","volume":"21","author":"Rau","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130733","article-title":"A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache","volume":"10","author":"Jackson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0025","first-page":"49","article-title":"Differential clinical profile of candesartan compared to other angiotensin receptor blockers","volume":"7","author":"Zimlichman","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0026","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40263-017-0430-3","article-title":"Pharmacokinetic variability of drugs used for prophylactic treatment of migraine","volume":"31","author":"Tfelt-Hansen","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11940-012-0208-3","article-title":"Familial and sporadic hemiplegic migraine: diagnosis and treatment","volume":"15","author":"Pelzer","year":"2013","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0028","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10194-009-0182-7","article-title":"Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome","volume":"11","author":"Haaland","year":"2010","journal-title":"J Headache Pain"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0029","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11940-008-0003-3","article-title":"Update on the prophylaxis of migraine","volume":"10","author":"Sch\u00fcrks","year":"2008","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-020-01106-5","article-title":"Headache medication and the COVID-19 pandemic","volume":"21","author":"MaassenVanDenBrink","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0031","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10072-008-0902-9","article-title":"Central mechanism of action of antimigraine prophylactic drugs","volume":"29","author":"Casucci","year":"2008","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0032","first-page":"1","article-title":"Clinical and vascular responses to propranolol and candesartan in migraine patients: a randomized controlled clinical trial","volume":"3","author":"Barzenje","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0033","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11916-004-0049-1","article-title":"Prophylactic migraine therapy: emerging treatment options","volume":"8","author":"Bigal","year":"2004","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0034","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1527-3466.2004.tb00146.x","article-title":"Candesartan","volume":"22","author":"Gleiter","year":"2004","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s13311-018-0621-8","article-title":"Current prophylactic medications for migraine and their potential mechanisms of action","volume":"15","author":"Sprenger","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0036","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1291\/hypres.27.441","article-title":"Efficacy of candesartan in the treatment of migraine in hypertensive patients","volume":"27","author":"Owada","year":"2004","journal-title":"Hypertens Res"},{"issue":"6","key":"10.1016\/j.clinthera.2025.06.003_bib0037","first-page":"CD010600","article-title":"Pharmacological agents for the prevention of vestibular migraine","volume":"2015","author":"Maldonado Fernandez","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.06.003_bib0038","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.hjh.0000220419.86149.11","article-title":"Involvement of the renin-angiotensin system in migraine","volume":"24","author":"Tronvik","year":"2006","journal-title":"J Hypertens Suppl"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:03:04Z","timestamp":1763787784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0149291825002073"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Candesartan for Treatment of Migraine Headache: A Scoping Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}